Muscle weakness and neuromuscular junctions in aging and disease

Geriatrics and Gerontology International

Volumn 10, Issue SUPPL. 1, 2010, Pages

  Shigemoto, Kazuhiro ^a   Kubo, Sachiho ^a   Mori, Syuuichi ^a   Yamada, Shigeru ^a   Akiyoshi, Takuyu ^a,b   Miyazaki, Tsuyoshi ^a  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Muscle specific kinase; Myasthenia gravis; Neuromuscular junction; Sarcopenia

Indexed keywords

AUTOANTIBODY; DOK 7 PROTEIN; IMMUNOGLOBULIN; LAMININ 1; MUSCLE SPECIFIC KINASE; PHOSPHOTRANSFERASE; PROTEIN; UNCLASSIFIED DRUG; CHOLINERGIC RECEPTOR; DOK7 PROTEIN, HUMAN; MUSCLE PROTEIN; MUSK PROTEIN, HUMAN; PROTEIN TYROSINE KINASE;

AGING; AUTOPHOSPHORYLATION; HUMAN; IMMUNIZATION; MOTONEURON; MOTOR NERVE; MOTOR SYSTEM; MUSCLE; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE REGENERATION; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STEM CELL; SYNAPTIC TRANSMISSION; ANIMAL; GENETICS; IMMUNOLOGY; LIMB GIRDLE MUSCULAR DYSTROPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; SARCOPENIA;

AGING; ANIMALS; HUMANS; MUSCLE PROTEINS; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; SARCOPENIA;

EID: 77954672969     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2010.00608.x     Document Type: Review

References (38)

1. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest 2006, 116:2843-2854.
2. Vincent A, Lang B, Kleopa KA. Autoimmune channelopathies and related neurological disorders. Neuron 2006, 52:123-138.
3. Patrick J, Lindstrom J. Autoimmune response to acetylcholine receptor. Science 1973, 180:871-872.
4. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001, 7:365-368.
5. Fambrough DM, Drachman DB, Satyamurti S. Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors. Science 1973, 182:293-295.
6. Engel AG, Sahashi K, Lamber EH, Howard FM. The Ulstrastructureal Localization of the Acetylcholine Receptor, Immunoglobulin G and the Third and Ninth Complement Components at the Moter End-Plate and Their Implications for the Pathogenesis of Myasthenia Gravis 1979, Amsterdam, Excerpta Medica
7. Katirji B. Electrodiagnosis of Neuromuscular Juncion Disorders 2003, New Jersey, Humana Press Inc.
8. Vincent A, Bowen J, Newsom-Davis J, McConville J. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol 2003, 2:99-106.
9. Evoli A, Tonali PA, Padua L. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003, 126:2304-2311.
10. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003, 60:1978-1980.
11. Yeh JH, Chen WH, Chiu HC, Vincent A. Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese. Neurology 2004, 62:2131-2132.
12. Ohta K, Shigemoto K, Kubo S. MuSK antibodies in AChR Ab-seropositive MG vs AChR Ab-seronegative MG. Neurology 2004, 62:2132-2133.
13. Ohta K, Shigemoto K, Kubo S. MuSK Ab described in seropositive MG sera found to be Ab to alkaline phosphatase. Neurology 2005, 65:1988.
14. Ohta K, Shigemoto K, Fujinami A, Maruyama N, Konishi T, Ohta M. Clinical and experimental features of MuSK antibody positive MG in Japan. Eur J Neurol 2007, 14:1029-1034.
15. Wolfe GI, Oh SJ. Clinical phenotype of muscle-specific tyrosine kinase-antibody-positive myasthenia gravis. Ann N Y Acad Sci 2008, 1132:71-75.
16. Evoli A, Bianchi MR, Riso R. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann N Y Acad Sci 2008, 1132:76-83.
17. Strochlic L, Cartaud A, Cartaud J. The synaptic muscle-specific kinase (MuSK) complex: new partners, new functions. Bioessays 2005, 27:1129-1135.
18. Kummer TT, Misgeld T, Sanes JR. Assembly of the postsynaptic membrane at the neuromuscular junction: paradigm lost. Curr Opin Neurobiol 2006, 16:74-82.
19. Glass DJ, Bowen DC, Stitt TN. Agrin acts via a MuSK receptor complex. Cell 1996, 85:513-523.
20. Kim N, Stiegler AL, Cameron TO. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell 2008, 135:334-342.
21. Zhang B, Luo S, Wang Q, Suzuki T, Xiong WC, Mei L. LRP4 serves as a coreceptor of agrin. Neuron 2008, 60:285-297.
22. Kong XC, Barzaghi P, Ruegg MA. Inhibition of synapse assembly in mammalian muscle in vivo by RNA interference. EMBO Rep 2004, 5:183-188.
23. Shigemoto K, Kubo S, Maruyama N. Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest 2006, 116:1016-1024.
24. Akaaboune M, Grady RM, Turney S, Sanes JR, Lichtman JW. Neurotransmitter receptor dynamics studied in vivo by reversible photo-unbinding of fluorescent ligands. Neuron 2002, 34:865-876.
25. Lindstrom J. Is " seronegative" MG explained by autoantibodies to MuSK? Neurology 2004, 62:1920-1921.
26. Shiraishi H, Motomura M, Yoshimura T. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 2005, 57:289-293.
27. Jha S, Xu K, Maruta T. Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J Neuroimmunol 2006, 175:107-117.
28. Shigemoto K, Sachiho K, Chen J. Experimentally induced myasthenia gravis with muscle-specific kinase. Ann N Y Acad Sci 2008, 1132:93-98.
29. DeChiara TM, Bowen DC, Valenzuela DM. The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell 1996, 85:501-512.
30. Wood SJ, Slater CR. Safety factor at the neuromuscular junction. Prog Neurobiol 2001, 64:393-429.
31. Chevessier F, Faraut B, Ravel-Chapuis A. MUSK, a new target for mutations causing congenital myasthenic syndrome. Hum Mol Genet 2004, 13:3229-3240.
32. Okada K, Inoue A, Okada M. The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. Science 2006, 312:1802-1805.
33. Beeson D, Higuchi O, Palace J. Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science 2006, 313:1975-1978.
34. Palace J, Lashley D, Newsom-Davis J. Clinical features of the DOK7 neuromuscular junction synaptopathy. Brain 2007, 130:1507-1515.
35. Slater CR, Fawcett PR, Walls TJ. Pre- and post-synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with " limb-girdle myasthenia" Brain 2006, 129:2061-2076.
36. Cole RN, Reddel SW, Gervasio OL, Phillips WD. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol 2008, 63:782-789.
37. Shigemoto K. Myasthenia gravis induced by autoantibodies against MuSK. Acta Myol 2007, 26:185-191.
38. Ezaki T, Oki S, Matsuda Y, Desaki J. Age changes of neuromuscular junctions in the extensor digitorum longus muscle of spontaneous thymoma BUF/Mna rats. A scanning and transmission electron microscopic study. Virchows Arch 2000, 437:388-395.